CASI Pharmaceuticals (CASI) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$10.8 million.
- Pharmaceuticals' Income towards Parent Company fell 2802.46% to -$10.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$29.4 million, marking a year-over-year decrease of 1384.49%. This contributed to the annual value of -$38.1 million for FY2024, which is 4356.45% down from last year.
- According to the latest figures from Q2 2025, Pharmaceuticals' Income towards Parent Company is -$10.8 million, which was down 2802.46% from -$10.1 million recorded in Q1 2025.
- In the past 5 years, Pharmaceuticals' Income towards Parent Company ranged from a high of -$3.3 million in Q4 2023 and a low of -$48.8 million during Q4 2022
- In the last 4 years, Pharmaceuticals' Income towards Parent Company had a median value of -$7.8 million in 2023 and averaged -$10.9 million.
- Over the last 5 years, Pharmaceuticals' Income towards Parent Company had its largest YoY gain of 9323.48% in 2023, and its largest YoY loss of 4747.3% in 2023.
- Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$48.8 million in 2022, then skyrocketed by 93.23% to -$3.3 million in 2023, then tumbled by 156.48% to -$8.5 million in 2024, then fell by 28.02% to -$10.8 million in 2025.
- Its Income towards Parent Company stands at -$10.8 million for Q2 2025, versus -$10.1 million for Q1 2025 and -$8.5 million for Q2 2024.